{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:15:10Z","timestamp":1783577710790,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Changzhou Guidance Program of Applied Basic Research","award":["CJ20229009"],"award-info":[{"award-number":["CJ20229009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-026-04235-4","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T13:57:06Z","timestamp":1770386226000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antitumor efficacy and molecular mechanism of lenvatinib combined with vitamin K2 against hepatocellular carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuli","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinggui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianfeng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongwei","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"2","key":"4235_CR1","first-page":"283","volume":"38","author":"General Office of National Health Commission","year":"2022","unstructured":"General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition). J Clin Hepatol. 2022;38(2):283\u2013303.","journal-title":"J Clin Hepatol"},{"key":"4235_CR2","doi-asserted-by":"crossref","unstructured":"Wu J, Zhang C, Zhang Y, et al. Prediction model establishment of prognosis factors for distant metastasis of hepatocellular carcinoma based on the SEER database. Cancer Epidemiol. 2024;94:102729.","DOI":"10.1016\/j.canep.2024.102729"},{"key":"4235_CR3","doi-asserted-by":"crossref","unstructured":"Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet. 2025;405:1851\u201364.","DOI":"10.1016\/S0140-6736(25)00403-9"},{"key":"4235_CR4","doi-asserted-by":"crossref","unstructured":"Cheon J, Shimose S, Kim HD, et al. Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan. J Cancer Res Clin Oncol. 2025;151:52.","DOI":"10.1007\/s00432-025-06085-1"},{"key":"4235_CR5","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s10147-025-02721-5","volume":"30","author":"K Yu","year":"2025","unstructured":"Yu K. Lenvatinib enhances antitumor immunity of anti-PD-1 antibody. Int J Clin Oncol. 2025;30:666\u201373.","journal-title":"Int J Clin Oncol"},{"issue":"10126","key":"4235_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-linetreatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163\u201373.","journal-title":"Lancet"},{"key":"4235_CR7","doi-asserted-by":"crossref","unstructured":"Lu X, Ma P, Kong L, et al. Vitamin K2 inhibits Hepatocellular Carcinoma cell proliferation by binding to 17\u03b2-Hydroxysteroid Dehydrogenase 4. Front Oncol. 2021;11:757603.","DOI":"10.3389\/fonc.2021.757603"},{"key":"4235_CR8","doi-asserted-by":"crossref","unstructured":"Mlad\u011bnka P, Mac\u00e1kov\u00e1 K, Kujovsk\u00e1 Kr\u010dmov\u00e1 L, et al. Vitamin K - sources, physiological role, kinetics, deficiency, detection, therapeutic use, and toxicity. Nutr Rev. 2021;80:677\u201398.","DOI":"10.1093\/nutrit\/nuab061"},{"key":"4235_CR9","unstructured":"He X, You J, Xiao D, et al. Effects of vitamin K2 on the growth and expression of HDGF in transplanted tumor of human liver cancer in nude mice. Chin J Exp Surg. 2019;36(10):1752\u20134."},{"issue":"9","key":"4235_CR10","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.6061\/clinics\/2012(09)18","volume":"67","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Zhang B, Zhang A, et al. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics. 2012;67(9):1093\u20139.","journal-title":"Clinics"},{"key":"4235_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3674","author":"Y Haruna","year":"2021","unstructured":"Haruna Y, Yakushijin T, Kawamoto S. Efficacy and safety of sorafenib plus vitamin K treatment for hepatocellular carcinoma: a phase II, randomized study. Cancer Med. 2021. https:\/\/doi.org\/10.1002\/cam4.3674.","journal-title":"Cancer Med"},{"key":"4235_CR12","doi-asserted-by":"crossref","unstructured":"Zhang YL, Zheng ZW, et al. Comprehensive analysis of competing endogenous RNA network focusing on long noncoding RNA involved in Cirrhotic Hepatocellular Carcinoma. Anal Cell Pathol. 2021;6:1\u201312.","DOI":"10.1155\/2021\/5510111"},{"issue":"3","key":"4235_CR13","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4235_CR14","doi-asserted-by":"crossref","unstructured":"Bi X, Zhao H, Zhao H, et al. Consensus of Chinese experts on neoadjuvant and conversion therapies for Hepatocellular Carcinoma: 2023 update. Liver Cancer. 2025;14:223\u20138.","DOI":"10.1159\/000541249"},{"key":"4235_CR15","doi-asserted-by":"crossref","unstructured":"Bureau of Medical Administration, National Health Commission of the People\u2019s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). J Clin Hepatol. 2020;36(2):277\u201392.","DOI":"10.21147\/j.issn.1000-9604.2019.02.02"},{"key":"4235_CR16","unstructured":"Qin CR, Zhang ZM, Yang B, et al. Apoptosis of hepatocellular carcinoma cell line Hep-G2 induced by vitamin K2. Chin J Cancer Prev Treat. 2017;24(24):1706\u201311."},{"key":"4235_CR17","doi-asserted-by":"crossref","unstructured":"Kuzuya T, Ishigami M, Ishizu Y, et al. Complete response by vitamin K2 analog monotherapy in sorafenib-failure advanced hepatocellular carcinoma: a case report. Hepatol Res. 2018;49:360\u20134.","DOI":"10.1111\/hepr.13237"},{"key":"4235_CR18","unstructured":"Zhang YF, Rao ZG, et al. Synergistic therapeutic effects of Sorafenib plus vitamin K2 on metastatic human Hepatocellular Carcinoma nude mice models [J]. Mil Med J S Chin. 2012;26(5):403\u20136."},{"key":"4235_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0925-4773(01)00457-9","volume":"107","author":"Y Lan","year":"2001","unstructured":"Lan Y, Kingsley PD, Cho ES, et al. Osr2, a new mouse gene related to Drosophila odd-skipped, exhibits dynamic expression patterns during craniofacial, limb, and kidney development. Mech Dev. 2001;107:175\u20139.","journal-title":"Mech Dev"},{"issue":"2","key":"4235_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bbrc.2010.06.054","volume":"398","author":"S Kawai","year":"2010","unstructured":"Kawai S, Abiko Y, Amano A. Odd-skipped related 2 regulates genes related to proliferation and development. Biochem Biophys Res Commun. 2010;398(2):184\u201390.","journal-title":"Biochem Biophys Res Commun"},{"key":"4235_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.bbrc.2012.04.064","volume":"421","author":"S Kawai","year":"2012","unstructured":"Kawai S, Amano A. Negative regulation of Odd-skipped related 2 by TGF-beta achieves the induction of cellular migration and the arrest of cell cycle. Biochem Biophys Res Commun. 2012;421:696\u2013700.","journal-title":"Biochem Biophys Res Commun"},{"key":"4235_CR22","doi-asserted-by":"crossref","unstructured":"Uysal D, Kriegmair MC, et al. A comprehensive molecular characterization of the 8q22.2 region reveals the prognostic relevance of OSR2 mRNA in muscle invasive bladder cancer. PLoS One. 2021;16(3):e0248342.","DOI":"10.1371\/journal.pone.0248342"},{"key":"4235_CR23","doi-asserted-by":"crossref","unstructured":"Li F, Yu H, Zhang Y, et al. F-box protein FBXO32 ubiquitinates and stabilizes D-type cyclins to drive cancer progression. Nat Commun. 2025;16:4060.","DOI":"10.1038\/s41467-025-59407-9"},{"issue":"9","key":"4235_CR24","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1101\/gad.1524107","volume":"21","author":"J Tan","year":"2007","unstructured":"Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21(9):1050.","journal-title":"Genes Dev"},{"issue":"3","key":"4235_CR25","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/labinvest.2009.138","volume":"90","author":"JL Chou","year":"2010","unstructured":"Chou JL, Su HY, Chen LY, et al. Promoter hypermethylation of FBXO32, a novel TGF-beta\/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest. 2010;90(3):414.","journal-title":"Lab Invest"},{"issue":"12","key":"4235_CR26","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1016\/j.celrep.2018.02.095","volume":"22","author":"JF Knight","year":"2018","unstructured":"Knight JF, Sung VYC, Kuzmin E, et al. KIBRA (WWC1) is a metastasis suppressor gene affected by chromosome 5q loss in triple-negative breast cancer. Cell Rep. 2018;22(12):3191\u2013205.","journal-title":"Cell Rep"},{"issue":"1","key":"4235_CR27","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20193176","volume":"40","author":"G Chen","year":"2020","unstructured":"Chen G, Yang Z, Feng M, et al. Microrna-217 suppressed epithelial-to-mesenchymal transition through targeting PTPN14 in gastric cancer. Biosci Rep. 2020;40(1):BSR20193176.","journal-title":"Biosci Rep"},{"issue":"10","key":"4235_CR28","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/sj.bjc.6604031","volume":"97","author":"M Niedergethmann","year":"2007","unstructured":"Niedergethmann M, Alves F, Neff JK, et al. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer. 2007;97(10):1432\u201340.","journal-title":"Br J Cancer"},{"issue":"1","key":"4235_CR29","first-page":"16","volume":"32","author":"N Ye","year":"2022","unstructured":"Ye N, Han M. Expression and clinical significance of PTPN14 in pancreatic adenocarcinoma. Chin J Hemorh. 2022;32(1):16\u201321.","journal-title":"Chin J Hemorh"}],"updated-by":[{"DOI":"10.1186\/s12957-026-04477-2","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000}}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-026-04235-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-026-04235-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T05:32:05Z","timestamp":1783575125000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-026-04235-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4235"],"URL":"https:\/\/doi.org\/10.1186\/s12957-026-04235-4","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Ethics section has been updated.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12957-026-04477-2","URL":"https:\/\/doi.org\/10.1186\/s12957-026-04477-2","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by Institutional Animal Care and Use Committee of Jiangsu Aniphe Biolaboratory Inc (No. JSAB26017M).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"115"}}